Prediction of vertebral fractures in cancer patients undergoing hormone deprivation therapies: Reliability of WHO fracture risk assessment tool (FRAX) and bone mineral density in real-life clinical practice

•In females under estrogen-deprivation therapies, risk of vertebral fractures was associated with FRAX score for major fractures, with the best therapeutic threshold of 6.5%.•In males under androgen-deprivation therapy, risk of vertebral fractures was high when BMD T-score was lower than −1.0 SD or when subjects were treated with abiraterone.•High body mass index was an independent risk factor for vertebral fractures in males exposed to androgen-deprivation therapy.•In the setting of hormonal deprivation therapies, FRAX and BMD thresholds were lower than those used in post-menopausal osteoporosis and primary male osteoporosis.